Benzimidazole-Based Derivatives as Apoptotic Antiproliferative Agents: Design, Synthesis, Docking, and Mechanistic Studies
Molecules · 16.01.2024 · 29 (2) · 446
DOI: 10.3390/molecules29020446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 16.01.2024. Verfasst von Bahaa G M Youssif und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Antineoplastic Agents. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KIT-Publication Fund of the Karlsruhe Institute of Technology.
Abstract (Originalsprache)
A new class of benzimidazole-based derivatives (4a–j, 5, and 6) with potential dual inhibition of EGFR and BRAFV600E has been developed. The newly synthesized compounds were submitted for testing for antiproliferative activity against the NCI-60 cell line. All newly synthesized compounds 4a–j, 5, and 6 were selected for testing against a panel of sixty cancer cell lines at a single concentration of 10 µM. Some compounds tested demonstrated remarkable antiproliferative activity against the cell lines tested. Compounds 4c, 4e, and 4g were chosen for five-dose testing against 60 human tumor cell lines. Compound 4c demonstrated strong selectivity against the leukemia subpanel, with a selectivity ratio of 5.96 at the GI50 level. The most effective in vitro anti-cancer assay derivatives (4c, 4d, 4e, 4g, and 4h) were tested for EGFR and BRAFV600E inhibition as potential targets for antiproliferative action. The results revealed that compounds 4c and 4e have significant antiproliferative activity as dual EGFR/BRAFV600E inhibitors. Compounds 4c and 4e induced apoptosis by increasing caspase-3, caspase-8, and Bax levels while decreasing the anti-apoptotic Bcl2 protein. Moreover, molecular docking studies confirmed the potential of compounds 4c and 4e to act as dual EGFR/BRAFV600E inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Nahda University, Beni-Suef 62513, Egypt.
- Institute of Biological and Chemical Systems, IBCS-FMS, Karlsruhe Institute of Technology, 76131 Karlsruhe, Germany.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Badr University in Assiut (BUA), Assiut 71536, Egypt.
ORCID-Profile: Bahaa G M Youssif, Stefan Bräse, Hamdy M Abdel-Rahman, El Shimaa M N Abdelhafez
Förderung
- KIT-Publication Fund of the Karlsruhe Institute of Technology
Zitieren
APA
Youssif, B. G. M., Morcoss, M. M., Bräse, S., Abdel-Aziz, M., Abdel-Rahman, H. M., Abou El-Ella, D. A., & Abdelhafez, E. S. M. N. (2024). Benzimidazole-Based Derivatives as Apoptotic Antiproliferative Agents: Design, Synthesis, Docking, and Mechanistic Studies. Molecules, 29(2), 446. https://doi.org/10.3390/molecules29020446
Vancouver
Youssif BGM, Morcoss MM, Bräse S, Abdel-Aziz M, Abdel-Rahman HM, Abou El-Ella DA, et al. Benzimidazole-Based Derivatives as Apoptotic Antiproliferative Agents: Design, Synthesis, Docking, and Mechanistic Studies. Molecules. 2024;29(2):446. doi:10.3390/molecules29020446
BibTeX
@article{Youssif2024,
author = {Youssif, Bahaa G M and Morcoss, Martha M and Bräse, Stefan and Abdel-Aziz, Mohamed and Abdel-Rahman, Hamdy M and Abou El-Ella, Dalal A and Abdelhafez, El Shimaa M N},
title = {Benzimidazole-Based Derivatives as Apoptotic Antiproliferative Agents: Design, Synthesis, Docking, and Mechanistic Studies},
journal = {Molecules},
year = {2024},
volume = {29},
number = {2},
pages = {446},
doi = {10.3390/molecules29020446}
}
EUVIMED